- AstraZeneca is paying Dizal $600 million upfront — plus up to $900 million more in milestone payments — for global rights to Sunvozertinib (Zegfrovy).
- The oral drug is approved in the U.S. and China for advanced non‑small cell lung cancer and showed longer progression‑free survival than chemotherapy (10.3 vs. 7.5 months) in a late‑stage trial.
- About 77% of lung cancers are non‑small cell, so the deal gives AstraZeneca a shot at a sizable market for a new targeted treatment.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.